Gland Pharma delivered in-line revenue in Q2 FY26. However, Ebitda/PAT came in below brokerage's expectations by 9%/11%. A lower than-expected share of milestone income and lower tech transfer/contract manufacturing organisation business in rest of world markets impacted Q2 FY26 performance.
NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
We lower our FY26 estimate by 3% and largely maintain our FY27/FY28 estimates. We value Gland Pharma Ltd. at 33 times 12 months forward earnings to arrive at a target price of Rs 2,310.
We expect a CAGR of 13%/18%/24% in sales/Ebitda/PAT over FY25-28 to Rs 81 billion/Rs 20.6 billion/Rs 13.5 billion, factoring-
revival in U.S. business on the back of product introduction,
increased revenue growth prospects in Cenexi post infrastructure upgrade, and
increasing capacity utilization of GLP-1 pens/cartridge for non-regulated market in the initial phase of patent expiries in these markets.
Maintain Buy.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
